Introduction {#s1}
============

Acute rejection is the major short-term challenge following kidney transplantation and it also increases long-term graft loss ([@B34]). Although induction therapy, human leukocyte antigen (HLA) mismatches, number of kidney transplants, living donor, and peak panel-reactive antibodies (PRAs) have been studied as potential acute rejection predictors ([@B14]; [@B28]; [@B29]; [@B59]), these factors only contribute partially to acute rejection incidence.

While the T-cell driven adaptive immune system is essential to acute rejection, the innate immune system also plays a key role. Extracellular damage-associated molecular patterns from transplantation surgery and ischemia/reperfusion injury can induce the translocation of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) into T-cell nuclei *via* activation of the myeloid differentiation primary response 88 (MyD88)-dependent Toll-like receptor (TLR) signaling pathway ([@B26]; [@B27]). Translocated NF-κB activates pro-inflammatory cytokine secretion \[e.g. pro-interleukin (IL)-1β, IL-2, and tumor necrosis factor-α (TNF-α)\] ([@B26]). Caspase 1 (encoded by *CASP1*) is an inflammatory response initiator and converts pro-IL-1β into mature IL-1β ([@B23]; [@B49]). These pro-inflammatory mediators can assist T-cell activation, proliferation, and differentiation, and intensify kidney tissue damage ([@B56]; [@B37]; [@B1]). In contrast, anti-inflammatory cytokines (e.g. IL-10) can decrease pro-inflammatory cytokine release ([@B54]) and therefore have the potential to attenuate rejection risk, whereas transforming growth factor β (TGF-β) and IL-6 have both pro- and anti-inflammatory action ([@B42]; [@B43]). Notably, IL-6 trans-signaling *via* soluble IL-6 receptor (IL-6R) is pro-inflammatory as it can enhance the expansion and activation of T- and B-cells and induce several acute phase reactants such as C-reactive protein (CRP) ([@B57]).

Single nucleotide polymorphisms (SNPs) in *CASP1*, *CRP*, *IL1B*, *IL2*, *IL6*, *IL6R*, *IL10*, *TGFB*, and *TNF* can increase or decrease the protein production and/or function of these pro- and anti-inflammatory mediators *in vitro* ([@B24]; [@B51]; [@B3]; [@B15]; [@B9]; [@B13]; [@B50]; [@B55]) or serum/plasma concentrations *in vivo* ([@B10]; [@B12]; [@B11]; [@B45]; [@B25]). In addition, SNPs in the MyD88-dependent TLR signaling pathway affect innate immune responses to vaccines ([@B39]) and susceptibility to infection or disease *in vivo* ([@B48]; [@B41]). Therefore, these innate immunogenetic markers may serve as predictors of acute rejection post-kidney transplantation.

Meta-analyses have shown that recipient and/or donor *IL2* -330T \> G (rs2069762), *IL10* -1082G \> A (rs1800896), -819C \> T (rs1800871), and -592C \> A (rs1800872), and *TNF* -308G \> A (rs1800629) SNPs do not affect acute rejection incidence in Caucasian kidney transplant recipients receiving immunosuppressive therapy ([@B21]; [@B16]; [@B58]; [@B17]). However, none of the cross-sectional studies included in these meta-analyses was carried out in recipients treated with tacrolimus (TAC) as the sole calcineurin inhibitor (CNI). Since TAC has potent immunosuppression 100 times greater than ciclosporin ([@B22]), with fewer rejection complications ([@B52]), most kidney transplant recipients in Europe and Australia have been treated with TAC as the first-choice CNI for immunosuppression therapy since 2003 ([@B53]) and 2009 ([@B2]), respectively. Therefore, it is worthwhile exploring the innate immunogenetic impact on kidney transplant recipients treated with only TAC as the CNI.

Only one study has investigated the impact of *IL1B* 3954C \> T (rs1143634) on acute rejection incidence in kidney transplant recipients and found recipient 3954C/T genotype had higher rejection incidence than C/C genotype (point-wise P = 0.045) but without multiple comparison adjustment ([@B31]). In terms of *TLR4* 896A \> G (rs4986790) and 1196C \> T (rs4986791), it is still controversial if these two SNPs affect acute rejection incidence in kidney transplant recipients ([@B8]; [@B40]; [@B38]). Limited sample size, low minor allele frequency of the *TLR4* SNPs, different criteria for acute rejection \[biopsy-proven acute rejection (BPAR) versus clinical evidence, e.g. serum creatinine change\], varied recipient/donor ethnicities, and different time of rejection post-transplantation between cross-sectional studies may contribute together to the inconsistent findings of *TLR4* genetics on acute rejection incidence. In addition, adjustment for multiple statistical comparisons was not conducted. Notably, SNPs in *CASP1*, *CRP*, *IL6R*, *MYD88*, and *TLR2* have not been examined for their impact on acute rejection in kidney transplant recipients.

To bridge these research gaps, this study aimed to explore the impact of recipient and donor *CASP1*, *CRP*, *IL1B*, *IL2*, *IL6*, *IL6R*, *IL10*, *MYD88*, *TGFB*, *TLR2*, *TLR4*, and *TNF* genotypes on BPAR incidence in a cohort of predominantly Caucasian kidney transplant recipients treated with TAC as the only CNI ([@B18]; [@B19]; [@B20]). We hypothesized that these recipient and donor innate immunogenetics would affect BPAR incidence in kidney transplant recipients in the first 2 weeks post-transplantation.

Materials and Methods {#s2}
=====================

Study Participants and Data Collection {#s2_1}
--------------------------------------

This study was approved by the Central Adelaide Local Health Network Human Research Ethics Committee (Protocol number 2008178). All procedures complied with the Declaration of Helsinki and/or institutional research committee ethical requirements.

As described previously, 165 kidney transplant recipients and 129 donors were recruited ([@B18]; [@B19]; [@B20]). All recipients and living donors gave written informed consent before participation. For deceased donors, their respective recipients gave informed consent to use excess donor tissue blood vessels for genotyping. Recipient inclusion and exclusion criteria, demographics, anti-CD-25 induction therapy, immunosuppressant regimen (TAC, mycophenolate mofetil, and prednisolone), the number of HLA mismatches (HLA-A, -B, and -DR antigens) between recipients and donors, number of kidney transplants, donor type (living or deceased), PRA scores (%), and BPAR based on Banff classification of [@B46] (as the transplants were performed between 2005 and 2011) have been described previously ([@B18]; [@B19]; [@B20]).

Genotyping {#s2_2}
----------

Genomic DNA was extracted from blood, buccal swab, and kidney tissue ([@B18]; [@B19]). A panel of 21 SNPs in 15 genes described previously ([@B36]; [@B4]; [@B6]; [@B47]; [@B5]) were assayed using Agena Bioscience (formerly known as Sequenom) MassARRAY at the Australian Genome Research Facility (Brisbane, Australia). This panel included SNPs in the MyD88-dependent TLR signaling pathway---*TLR2* 1350T \> C (rs3804100), *TLR4* 896A \> G and 1196C \> T, and *MYD88* 1593A \> G (rs6853); pro- and anti-inflammatory mediators---*CASP1* 5352G \> A (rs580253) and 10643G \> C (rs554344), *CRP* -717T \> C (rs2794521), *IL1B* -511C \> T (rs16944), -31T \> C (rs1143627), and -3954C \> T, *IL2* -330T \> G, *IL6* -6331T \> C (rs10499563), *IL6R* -48892A \> C (rs8192284), *IL10* -1082G \> A and -819C \> T, *TGFB* -509C \> T (rs1800469), and *TNF* -308G \> A. The panel also included *BDNF* 196G \> A (rs6265) and *OPRM1* 118A \> G (rs1799971) that were considered outside the scope of this study, and *TGFB* -1287G \> A (rs11466314) and *LY96* 379C \> T (rs11466004) that are known to be of very low frequency in Caucasians; these four SNPs were therefore not included in the analyses described below.

Statistical Analyses {#s2_3}
--------------------

Hardy-Weinberg Equilibrium (HWE) tests for all genotypes, linkage disequilibrium (LD) between SNPs and haplotype inference within genes, and logistic regression analyses, were as described previously ([@B18]; [@B19]). Due to the relatively limited sample size, only SNPs with minor allele frequencies \>5% were included in logistic regression analyses. For SNPs in perfect or near-perfect (r^2^ \> 0.9) LD, only 1 of the linked SNPs in that gene, instead of haplotypes/diplotypes, was analyzed in logistic regression analysis.

Genotype differences in BPAR incidence were analyzed for each SNP separately by logistic regression, adjusting for induction therapy \[yes/no (Y/N)\], living donor (Y/N), HLA mismatches (\<3 or ≥3), kidney transplant number (1 or ≥ 2), and peak PRA scores (≤10% or \>10%). Statistical significance was assessed by the likelihood-ratio test, and effects described by odds ratios (OR) with 95% confidence intervals (CI). Genotype differences in BPAR without adjusting for non-genetic variables were tested by Cochran-Armitage test for trend in GraphPad Prism v8 (GraphPad Software, San Diego, CA, USA), or Fisher's exact test for SNPs with rare homozygous genotypes (n \< 5) combined with heterozygotes, and OR with 95% CI.

P-value thresholds for significance were corrected for multiple testing by Bonferroni-adjustment (α = 0.05/N, where N is the number of SNPs analyzed in the recipient or donor cohort, respectively).

Results {#s3}
=======

One hundred and fifty-four recipients and 81 (57 living, 24 deceased) donors had sufficient DNA for genotyping. In total, 23% (n = 35) of recipients with genotype data developed BPAR in the first 2 weeks post-transplantation. The impact of induction therapy, HLA mismatches, kidney transplant number, living donor, and peak PRA scores on BPAR incidence has been reported ([@B19]); none were statistically significant (likelihood-ratio test P-value \> 0.1).

Genetic Variability in Kidney Transplant Recipients and Donors {#s3_1}
--------------------------------------------------------------

All recipient and donor allele and genotype frequencies are summarized in [**Table 1**](#T1){ref-type="table"}. Six recipients each received a kidney from three deceased donors (two kidneys per donor), therefore, these three donors were counted only once for HWE tests but were treated independently for logistic regression analyses. For some SNPs, one to four recipients and/or donors had missing genotypes due to genotyping failure. All recipient and donor genotypes were in HWE (P ≥ 0.2). *CASP1*, *IL1B*, *IL10*, and *TLR4* haplotype and diplotype frequencies are summarized in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. Recipient and donor *CASP1* 10643G and 5352G, *IL1B* -511C and -31T, and *TLR4* 896A and 1196C were in perfect or near-perfect LD (D' \> 0.99; r^2^ ≥ 0.96) while *IL10* -1082G and -819C were in complete but not perfect LD \[D' = 1.0; r^2^ = 0.30; resulting in six observed diplotypes ([**Supplementary Table 1**](#SM1){ref-type="supplementary-material"})\]. Therefore, only 5352G \> A in *CASP1*, -511C \> T and 3954C \> T in *IL1B*, and 896A \> G in *TLR4*, along with all SNPs (including *IL10* -1082G \> A and -819C \> T separately) in other innate immune genes, were included in the subsequent analyses.

###### 

Recipient and donor genotype and allele frequencies of SNPs in pro- and anti-inflammatory mediators and MyD88-dependent TLR signaling pathway genes.

  Genes & SNPs   Recipients^\#^ (n = 153--154)   Donors\* (n = 77--81)                                                              
  -------------- ------------------------------- ----------------------- -------------- -------------- -------------- ------------- -----
  *CASP1*        5352G \> A                      G/G (107, 69)           G (258, 84)    0.8            G/G (58, 72)   G (137, 85)   1
  G/A (44, 29)   A (50, 16)                                              G/A (21, 26)   A (25, 15)                                  
  A/A (3, 2)                                                             A/A (2, 2)                                                 
  10643G \> C    G/G (107, 69)                   G (258, 84)             0.8            G/G (58, 72)   G (137, 85)    1             
  G/C (44, 29)   C (50, 16)                                              G/C (21, 26)   C (25, 15)                                  
  C/C (3, 2)                                                             C/C (2, 2)                                                 
  *CRP*          -717T \> C                      T/T (77, 50)            T (215, 70)    0.4            T/T (33, 41)   T (103, 64)   1
  T/C (61, 40)   C (93, 30)                                              T/C (37, 46)   C (57, 36)                                  
  C/C (16, 10)                                                           C/C (10, 13)                                               
  *IL1B*         -511C \> T                      C/C (76, 49)            C (215, 70)    0.7            C/C (41, 51)   C (114, 70)   0.8
  C/T (63, 41)   T (93, 30)                                              C/T (32, 40)   T (48, 30)                                  
  T/T (15, 10)                                                           T/T (8, 10)                                                
  -31T \> C      T/T (74, 48)                    T (211, 69)             0.7            T/T (41, 51)   T (114, 70)    0.8           
  T/C (63, 41)   C (95, 31)                                              T/C (32, 40)   C (48, 30)                                  
  C/C (16, 10)                                                           C/C (8, 10)                                                
  3954C \> T     C/C (84, 55)                    C (229, 74)             0.5            C/C (52, 64)   C (128, 79)    0.5           
  C/T (61, 40)   T (79, 26)                                              C/T (24, 30)   T (34, 21)                                  
  T/T (9, 6)                                                             T/T (5, 6)                                                 
  *IL2*          -330T \> G                      T/T (70, 45)            T (203, 66)    0.3            T/T (39, 48)   T (114, 70)   0.6
  T/G (63, 41)   G (105, 34)                                             T/G (36, 44)   G (48, 30)                                  
  G/G (21, 14)                                                           G/G (6, 7)                                                 
  *IL6*          -6331T \> C                     T/T (80, 52)            T (221, 72)    0.8            T/T (50, 62)   T (128, 79)   1
  T/C (61, 40)   C (87, 28)                                              T/C (28, 35)   C (34, 21)                                  
  C/C (13, 8)                                                            C/C (3, 4)                                                 
  *IL6R*         48892 \> C                      A/A (50, 33)            A (178, 58)    0.6            A/A (27, 34)   A (93, 58)    1
  A/C (78, 51)   C (128, 42)                                             A/C (39, 49)   C (67, 42)                                  
  C/C (25, 16)                                                           C/C (14, 18)                                               
  *IL10*         -1082G \> A                     G/G (31, 20)            G (141, 46)    0.6            G/G (16, 20)   G (68, 42)    0.5
  G/A (79, 52)   A (165, 54)                                             G/A (36, 44)   A (94, 58)                                  
  A/A (43, 28)                                                           A/A (29, 36)                                               
  -819C \> T     C/C (88, 58)                    C (230, 75)             0.5            C/C (42, 52)   C (119, 73)    0.4           
  C/T (54, 35)   T (76, 25)                                              C/T (35, 43)   T (43, 27)                                  
  T/T (11, 7)                                                            T/T (4, 5)                                                 
  *MYD88*        1593A \> G                      A/A (123, 80)           A (275, 89)    0.7            A/A (64, 79)   A (145, 90)   0.6
  A/G (29, 19)   G (33, 11)                                              A/G (17, 21)   G (17, 10)                                  
  G/G (2, 1)                                                             G/G (0, 0)                                                 
  *TGFB*         -509C \> T                      C/C (81, 53)            C (222, 72)    0.8            C/C (45, 56)   C (119, 73)   0.6
  C/T (60, 39)   T (86, 28)                                              C/T (29, 36)   T (43, 27)                                  
  T/T (13, 8)                                                            T/T (7, 9)                                                 
  *TLR2*         1350T \> C                      T/T (133, 86)           T (285, 93)    0.2            T/T (74, 91)   T (154, 95)   0.2
  T/C (19, 12)   C (23, 7)                                               T/C (6, 7)     C (8, 5)                                    
  C/C (2, 1)                                                             C/C (1, 1)                                                 
  *TLR4*         896A \> G                       A/A (137, 89)           A (290, 94)    0.4            A/A (71, 88)   A (152, 94)   1
  A/G (16, 10)   G (18, 6)                                               A/G (10, 12)   G (10, 6)                                   
  G/G (1, 1)                                                             G/G (0, 0)                                                 
  1196C \> T     C/C (136, 88)                   C (289, 94)             0.4            C/C (70, 88)   C (150, 94)    1             
  C/T (17, 11)   T (19, 6)                                               C/T (10, 13)   T (10, 6)                                   
  T/T (1, 1)                                                             T/T (0, 0)                                                 
  *TNF*          -308G \> A                      G/G (113, 73)           G (261, 85)    0.2            G/G (50, 62)   G (130, 80)   0.2
  G/A (35, 23)   A (47, 15)                                              G/A (30, 37)   A (32, 20)                                  
  A/A (6, 4)                                                             A/A (1, 1)                                                 

HWE P, Hardy-Weinberg Equilibrium P-value; n, number; SNP, single nucleotide polymorphism.

Donors\*: donor numbers may differ from those in [**Table 2**](#T2){ref-type="table"}, as 3 deceased donors each provided kidneys for 6 different recipients, these 3 donors were not counted twice in HWE; also, donor numbers may differ within [**Table 1**](#T1){ref-type="table"} due to genotyping failure.

Recipients ^\#^: recipient numbers may differ within [**Table 1**](#T1){ref-type="table"} due to genotyping failure.

Rare homozygous genotypes (n \< 5) were combined with heterozygous genotypes for logistic regression and Fisher's exact test as follows: recipient *MYD88* rs6853 A/A genotype versus G allele carriers (A/G + G/G), *TLR4* 896A/A genotype versus G allele carriers (A/G + G/G); donor *IL6* -6331T/T genotype versus C allele carriers (T/C + C/C); recipient and donor *CASP1* 5352G/G genotype versus A allele carriers (G/A + A/A), *TLR2* 1350T/T genotype versus C allele carriers (T/C + C/C), *TNF* -308G/G genotype versus A allele carriers (G/A + A/A).

Consequently, a multiple testing-adjusted P-value threshold for significance was determined at 0.0036 (α = 0.05/14).

Innate Immunogenetic Impact on BPAR Incidence {#s3_2}
---------------------------------------------

[**Table 2**](#T2){ref-type="table"} summarizes the associations between recipient and donor genotypes and BPAR incidence in the first 2 weeks post-transplantation, adjusting for induction therapy, HLA mismatches, kidney transplant number, living donor, and peak PRA scores. Although recipients with *IL6* -6331C/C genotype had a higher incidence of BPAR compared to T/T genotype recipients \[OR (95% CI) = 6.6 (1.7--25.8), likelihood-ratio test P-value = 0.017\], none of the genetic factors (including *IL6* -6331T \> C) statistically significantly affected BPAR incidence after correction for multiple comparisons (P-value threshold = 0.0036).

###### 

Recipient and Donor Innate Immune Genotype Differences in BPAR Incidence in the first 2 Weeks Post-Transplantation, Adjusting for HLA Mismatches, Induction Therapy, Kidney Transplant Number, Living Donor and Peak PRA Scores.

  Genes & SNPs     Recipients^\#^ (n = 153--154)   Donors\* (n = 83--84)                                                                            
  ---------------- ------------------------------- ----------------------- -------- ---------------- ---------- ------------------- -------- ------ ------
  *CASP1*          5352G \> A                      G/G (107)               19, 18   Ref              0.07       G/G (60)            16, 27   Ref    0.9
  G/A + A/A (47)   16, 34                          2.2 \[0.9--5.2\]                 G/A + A/A (24)   7, 29      1.0 \[0.3--2.9\]                    
  *CRP*            -717T \> C                      T/T (77)                12, 16   Ref              0.05       T/T (34)            6, 18    Ref    0.1
  T/C (61)         18, 30                          3.0 \[1.2--7.6\]                 T/C (39)         15, 38     3.1 \[1.0--10.5\]                   
  C/C (16)         5, 31                           2.1 \[0.5--7.8\]                 C/C (10)         2, 20      1.3 \[0.2--7.5\]                    
  *IL1B*           -511C \> T                      C/C (76)                18, 24   Ref              0.9        C/C (41)            13, 32   Ref    0.5
  C/T (63)         13, 21                          0.8 \[0.3--1.9\]                 C/T (34)         9, 26      0.7 \[0.2--2.2\]                    
  T/T (15)         4, 27                           0.9 \[0.2--3.6\]                 T/T (9)          1, 11      0.3 \[0.01--1.9\]                   
  3954C \> T       C/C (84)                        16, 19                  Ref      0.2              C/C (54)   13, 24              Ref      0.07   
  C/T (61)         18, 30                          2.0 \[0.9--4.6\]                 C/T (25)         10, 40     2.3 \[0.8--6.6\]                    
  T/T (9)          1, 11                           0.6 \[0.03--4.1\]                T/T (5)          0, 0       NA                                  
  *IL2*            -330T \> G                      T/T (70)                12, 17   Ref              0.3        T/T (41)            10, 24   Ref    0.09
  T/G (63)         16, 25                          1.5 \[0.6--3.6\]                 T/G (37)         9, 24      1.1 \[0.4--3.2\]                    
  G/G (21)         7, 33                           2.4 \[0.7--7.2\]                 G/G (6)          4, 67      8.1 \[1.2--78.5\]                   
  *IL6*            -6331T \> C                     T/T (80)                14, 18   Ref              0.02       T/T (52)            11, 21   Ref    0.09
  T/C (61)         15, 25                          1.6 \[0.7--4.0\]                 T/C + C/C (32)   12, 38     2.4 \[0.9--6.9\]                    
  C/C (13)         6, 46                           6.6 \[1.7--25.8\]                                                                                
  *IL6R*           48892A \> C                     A/A (50)                12, 24   Ref              0.9        A/A (29)            4, 14    Ref    0.09
  A/C (78)         16, 21                          0.8 \[0.3--2.1\]                 A/C (39)         11, 28     2.3 \[0.6--10.1\]                   
  C/C (25)         6, 24                           0.9 \[0.3--3.2\]                 C/C (15)         7, 47      5.4 \[1.2--27.5\]                   
  *IL10*           -1082G \> A                     G/G (31)                8, 26    Ref              0.7        G/G (18)            3, 17    Ref    0.4
  G/A (79)         19, 24                          1.0 \[0.4--2.9\]                 G/A (37)         11, 30     2.3 \[0.6--11.8\]                   
  A/A (43)         8, 19                           0.7 \[0.2--2.3\]                 A/A (29)         9, 31      2.5 \[0.6--13.3\]                   
  -819C \> T       C/C (88)                        22, 25                  Ref      0.4              C/C (44)   9, 20               Ref      0.05   
  C/T (54)         10, 19                          0.6 \[0.2--1.4\]                 C/T (36)         14, 39     2.7 \[1.0--7.9\]                    
  T/T (11)         3, 27                           1.2 \[0.2--4.6\]                 T/T (4)          0, 0       NA                                  
  *MYD88*          1593A \> G                      A/A (123)               28, 23   Ref              0.6        A/A (66)            17, 26   Ref    0.5
  A/G + G/G (31)   7, 23                           0.7 \[0.2--2.0\]                 A/G (18)         6, 33      1.5 \[0.4--4.7\]                    
  *TGFB*           -509C \> T                      C/C (81)                18, 22   Ref              0.7        C/C (47)            14, 30   Ref    0.5
  C/T (60)         13, 22                          1.0 \[0.4--2.3\]                 C/T (29)         6, 21      0.5 \[0.2--1.7\]                    
  T/T (13)         4, 31                           1.7 \[0.4--6.1\]                 T/T (8)          3, 38      1.3 \[0.2--6.2\]                    
  *TLR2*           1350T \> C                      T/T (133)               33, 25   Ref              0.07       T/T (77)            22, 29   Ref    0.5
  T/C + C/C (21)   2, 10                           0.3 \[0.04--1.1\]                T/C + C/C (7)    1, 14      0.5 \[0.02--3.4\]                   
  *TLR4*           896A \> G                       A/A (137)               31, 23   Ref              0.7        A/A (74)            20, 27   Ref    0.9
  A/G + G/G (17)   4, 24                           1.3 \[0.3--4.3\]                 A/G (10)         3, 30      0.9 \[0.2--3.8\]                    
  *TNF*            -308G \> A                      G/G (113)               21, 19   Ref              0.04       G/G (53)            13, 25   Ref    0.5
  G/A + A/A (41)   14, 34                          2.4 \[1.0--5.7\]                 G/A + A/A (31)   10, 32     1.4 \[0.5--3.8\]                    

BPAR, biopsy-proven acute rejection; HLA, human leukocyte antigens (HLA-A, -B, and -DR) mismatches; n, number; NA, not available; OR, odds ratio; P, likelihood-ratio P-value; peak PRAs, peak panel-reactive antibodies scores assessed by serum lymphocytotoxicity assay; Ref, reference group; SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval.

Donors\*, donor numbers may differ from those in [**Table 1**](#T1){ref-type="table"}, as each of the 3 deceased donors provided kidneys for 6 different recipients, these 3 donors were counted only once for HWE tests but they were treated independently when associated with BPAR for the individual recipients. In addition, donor numbers may differ within [**Table 2**](#T2){ref-type="table"} due to genotyping failure.

Recipients^\#^, recipient numbers may differ within [**Table 1**](#T1){ref-type="table"} due to genotyping failure.

In univariate analysis, there was a trend of increasing BPAR incidence for recipient *IL6* -6331T \> C (18% in T/T, 25% in T/C, and 46% in C/C; Cochran-Armitage P = 0.031), although it was non-statistically significant after correcting for multiple comparisons (P-value threshold = 0.0036). Similar trends of increasing BPAR incidence were observed in recipient *CRP* -717T \> C (16% in T/T, 30% in T/C, and 31% in C/C; Cochran-Armitage P = 0.048), recipient *CASP1* 5352G \> A (18% in G/G, 34% in G/A, and 33% in A/A; Cochran-Armitage P = 0.033) and donor *IL6R* -48892A \> C (15% in A/A, 28% in A/C, and 47% in C/C; Cochran-Armitage P = 0.019). Point-wise Cochran-Armitage and Fisher's exact test P-values were \> 0.05 for all other recipient and donor SNPs.

[**Supplementary Table 2**](#SM1){ref-type="supplementary-material"} summarizes recipient and donor genotype differences in BPAR incidence in the first 2 weeks post-transplantation for all 21 SNPs included in the genotyping panel.

Discussion {#s4}
==========

To our knowledge, this is the first innate immunogenetic study retrospectively investigating both recipient and donor genetics of pro- and anti-inflammatory mediators for their impact on BPAR incidence in kidney transplant recipients receiving only TAC as the CNI.

The *IL6* -6331 T/T genotype was associated with up to 6-fold higher plasma IL-6 concentrations than C allele carriers in acute inflammatory-status patients post-coronary artery bypass grafting surgery and in patients requiring intensive periodontal therapy, whereas no significant impact was found in healthy volunteers ([@B45]). However, the relationship between -6331T \> C genotypes and plasma IL-6 concentration has not previously been examined post-kidney transplantation, nor the impact of these genotypes on BPAR incidence in kidney transplant recipients. Our results indicate that recipient C/C genotype is associated with 6.6-fold higher odds of BPAR, and with a genotype trend of increasing BPAR incidence from T/T (18%) to T/C (25%) to C/C (46%). However, probably due to a limited sample size (see [**Table 2**](#T2){ref-type="table"}), the impact of -6331T \> C on BPAR incidence was not statistically significant after adjusting for multiple comparisons. Although a recent liver transplant study also failed to show a significant relationship between -6331T \> C and BPAR incidence, its sample size was even smaller (liver transplant recipient and donor n = 29; BPAR n = 8), and there were no recipients with the -6331 C/C genotype ([@B5]). Therefore, the impact of the *IL6* -6331T \> C on inflammation and BPAR incidence is still uncertain, and more studies with larger sample sizes are needed to elucidate if this SNP affects BPAR incidence in kidney transplant recipients.

In terms of the impact of *IL2* -330T \> G, *IL10* -1082G \> A, and *TNF* -308G \> A on BPAR incidence, our results are in accordance with previous meta-analyses ([@B21]; [@B16]; [@B58]; [@B17]) indicating these SNPs are not significant determinants of BPAR incidence in Caucasian kidney transplant recipients receiving TAC or ciclosporin. Our study also supports cross-sectional studies in which *IL1B* -511C \> T did not affect BPAR incidence in kidney transplant recipients receiving TAC or ciclosporin ([@B32]; [@B33]; [@B31]; [@B44]; [@B7]). Some studies reported that *IL1B* 3954C \> T and *TLR4* 896A \> G and 1196C \> T affected BPAR incidence but without multiple comparison adjustment ([@B8]; [@B40]; [@B31]). These findings were not reproduced in our cohort and in another kidney transplant study exploring the relationship between *TLR4* genetics and BPAR incidence ([@B38]). We are not aware of any other kidney transplant studies investigating the impact of these three SNPs on BPAR incidence in kidney transplant recipients. Recipient and donor *CASP1*, *CRP*, *IL6R*, *MYD88*, and *TLR2* genetics were expected to be important for any innate immune contribution to BPAR incidence in kidney transplant patients, however, common variants in these genes had no significant impact on BPAR incidence in our study. Overall, these results suggest that the innate immunogenetic SNPs investigated (except for *IL6*-6331T \> C) are not likely to contribute greatly to BPAR incidence in the first 2 weeks following transplantation in Caucasian kidney transplant recipients receiving immunosuppressive therapy.

Our study has several limitations to consider when interpreting the results. Firstly, as a retrospective study, the limited sample size (recipient and donor n = 151 and 81, respectively) may have been insufficient to support the findings of no major innate immunogenetic impact on BPAR incidence. However, the data presented in this study, along with other innate immunogenetic studies may together provide valuable information for future meta-analyses investigating the impact of innate immunogenetics on BPAR incidence. Secondly, it was necessary to combine some rare homozygous genotypes for statistical purposes; thus the effect of certain rare homozygous genotypes is unknown. Thirdly, some additional SNPs, e.g. *IL6* -174G \> C (rs1800795) and *IL10* -592C \> A ([@B30]; [@B58]) were not included in this study because of incompatibility with the genotyping array, and insufficient DNA was available to carry out separate genotyping of these SNPs. In addition, other important innate immune genes, e.g. *NFKB1* (encoding for the NF-κB1 subunit) ([@B35]), were not included in the gene panel design and are worthwhile exploring in the future for their impact on BPAR incidence.

In conclusion, this study did not detect any statistically significant impact of recipient and donor innate immune genetics on BPAR incidence in the first 2 weeks post-kidney transplantation. However, due to the limited sample size, future immunogenetic studies and/or meta-analyses are still required to demonstrate conclusively if innate immune genetics such as *IL6* -6331T \> C influence the risk of BPAR incidence post-kidney transplantation.
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